Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited announced a significant transformation initiative aimed at enhancing its operational efficiency and shareholder value. The company reported a 17% increase in net profit after tax for the fiscal year 2025, driven by strong performances in its CSL Behring and CSL Vifor segments. The strategic plan includes a demerger of CSL Seqirus, a share buyback program, and a focus on cost savings and reinvestment in growth opportunities. These changes are expected to streamline operations, reduce costs, and foster sustainable growth, although they will result in a 15% reduction in the workforce and restructuring costs of up to $770 million.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company primarily engaged in the development and delivery of innovative biotherapies and influenza vaccines. The company operates through its key segments: CSL Behring, which focuses on plasma therapies; CSL Seqirus, which specializes in influenza vaccines; and CSL Vifor, which is involved in nephrology and iron deficiency treatments. CSL is committed to advancing its market position by leveraging its robust research and development capabilities and optimizing its operational efficiencies.
YTD Price Performance: -3.21%
Average Trading Volume: 743,260
Technical Sentiment Signal: Buy
Current Market Cap: A$130.9B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.